The largest community of pharma leaders

Beam Therapeutics Appoints Brian Riley as Senior Vice President of Technical Operations

CAMBRIDGE, Mass.–()–Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Brian Riley as Senior Vice President of Technical Operations.

“I am tremendously excited to welcome Brian to our growing team,” said John Evans, chief executive officer of Beam. “Brian’s leadership will be invaluable to Beam as we progress our pipeline of base editing programs. Base editing represents a potential new class of genetic medicines that can offer an important new treatment option for patients suffering from serious diseases.”

Mr. Riley brings to Beam more than 20 years of biotech operational and manufacturing experience across diverse manufacturing modalities covering drug substance, drug product, and packaging, as well as facility design, construction and startup, and global multisite leadership. He joins Beam from Catalent Pharma Solutions, where he led the company’s biologics business over the past five years and managed five biologics plants across North America and Europe. Prior to Catalent, he served as the site director of Durham, NC operations at bioMerieux, where he led both the company’s compliance remediation effort and global growth platform. Before bioMerieux, he held progressive roles through quality and operations at Biogen Idec, Amgen and Diosynth Biotechnology. Mr. Riley holds an MBA from Campbell University and a B.S. from North Carolina State University.

“Throughout my career within the biotech industry, I have been fortunate to support a number of companies that have been successful in developing innovative technologies that benefit patients in need,” said Mr. Riley. “Since launching last year, the Beam team has made instrumental progress advancing its base editing technology and pipeline for the betterment of patients. Beam’s technology represents a tremendously exciting and novel approach to precision genetic medicine, and I am honored to join this talented team at this point in the company’s evolution.”

About Beam Therapeutics

Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Beam is headquartered in Cambridge, Massachusetts. For additional information, visit www.BeamTx.com.

Source

Recent Articles

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene...

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)-- #NeurofibromatosisTreatment--The Asia Pacific is expected to witness significant growth...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food...

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today initiatives to bring attention to...

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.